Premium
Pharmacist‐Designed and ‐Implemented Pharmaceutical Care Plan for Antipsychotic‐Induced Movement Disorders
Author(s) -
Stoner Steven C.,
Worrel Jodi A.,
Jones Michael T.,
Farrar Cynthia A.,
Ramlatchman Leonard V.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.6.583.35159
Subject(s) - pharmaceutical care , anticholinergic , medicine , intervention (counseling) , clinical pharmacy , dyskinesia , antipsychotic , pharmacist , intensive care medicine , psychiatry , schizophrenia (object oriented programming) , pharmacy , nursing , disease , parkinson's disease
We developed a systematic approach to assess the presence, severity, and management of extrapyramidal symptoms (EPS) in patients treated with antipsychotics. Patients were evaluated by the Modified Simpson‐Angus scale, Abnormal Involuntary Movement Scale, and Dyskinesia Identification System: Condensed User Scale. We completed 235 sets of evaluations in 83 patients. A pharmaceutical intervention was proposed in 54% (130) of evaluations, of which 82% (107) were accepted and followed. In 93% (99) evaluations in which a recommendation was followed, clinical outcome was positive. The most common intervention was reducing the dosage or discontinuing the antidyskinetic agent, most often an anticholinergic (55% of cases). Our results show that detailed monitoring of EPS in a clinical pharmacist‐operated clinic promotes rational drug therapy, limits unnecessary drugs, and improves clinical outcome of patients with EPS.